DanCann Pharma A/S has appointed Peter Søndergaard as new fulltime CFO

COPENHAGEN, Denmark, 4 January 2023 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, hereby announces that the Company has appointed Peter Søndergaard as new Chief Financial Officer (“CFO”).

Peter Søndergaard, who holds a Master of Science in Strategy and Management, has more than 15 years of experience from C-level employment in production and sales companies. At DanCann Pharma, Peter Søndergaard will lead the finance function in the growing organization, which consists of DanCann Pharma A/S and the subsidiary CannGros ApS. He will be responsible for developing and implementing relevant financial management tools adapted to the individual business areas in collaboration with the executive management team, of which he will be a part together with CEO Jeppe Krog Rasmussen, COO Sarah Mai Holm and CEO in the subsidiary CannGros, Louise Conradsen.

Jeppe Krog Rasmussen, CEO of DanCann Pharma, comments:

- For some time, we have had an interim CFO (consultant) on reduced hours, but in line with the commercialization of the business and our increasing focus on operations and optimization, we need a permanent, full resource who can help transform the finance function from simply accounting focus to finance/business focus. We have continuously been looking for the right profile, and we are convinced that we have found that in Peter. He has the necessary broad experience in working with business processes throughout the finance function and I am sure that Peter's versatility will help at DanCann Pharma, where he will be empowered to put his own mark on the finance function.

Peter Søndergaard is looking forward to getting started at DanCann Pharma - and to contribute to the organization’s goals, growth and profitability.

Peter Søndergaard elaborates:

- For several years, the key focus of my work has been the transformation of finance departments, where I have used my role in finance to actively create a strong foundation with a modern finance function by means of optimizing processes and digitalization. I have a proactive approach to my work and am at the same time driven by a strong desire to create results through motivating my colleagues' drive and commitment. DanCann Pharma is a young, ambitious company with clear goals for the future and a committed and competent team of employees, of which I look forward to becoming a part.

Peter Søndergaard has joined the Company from the beginning of January together with two more new colleagues. DanCann Pharma has 18 employees from January 2023.

About DanCann Pharma

DanCann Pharma A/S (SS: DANCAN) was founded in 2018 and is a Danish biopharmaceutical Company powered by cannabinoids. DanCann Pharma is a vertically integrated, licensed production and distribution Company based in Denmark. The Company focuses on discovering, developing, manufacturing, and commercializing new therapeutic cannabinoids in a wide range of disease areas. DanCann Pharma A/S (SS: DANCAN) is listed on the Spotlight Stock Market in Copenhagen.

For more information, visit: www.dancann.com.

For further information, please contact:

Jeppe Krog Rasmussen, CEO

E-mail: [email protected]  

Website: www.dancann.com  

Forward looking statement

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events, or developments that the Company believes, expects, or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology.

Forward-looking statements are subject to several risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities.

Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this presentation are made as of the date of this presentation and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.